久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Granules gets US FDA nod for OTC naproxen sodium and diphenhydramine hydrochloride tablets

expresspharmaSeptember 27, 2020

Tag: granules india , FDA , naproxen sodium , diphenhydramine hydrochloride tablets

Granules India announced that the US Food & Drug Administration (US FDA) has approved its abbreviated new drug application (ANDA) for naproxen sodium and diphenhydramine hydrochloride tablets, 220 mg/25 mg (OTC), generic equivalent of Aleve PM Tablets, 220 mg/25 mg, of Bayer HealthCare.

Naproxen sodium and diphenhydramine hydrochloride tablets are used for relief of occasional sleeplessness associated with minor aches and pains and to help you fall asleep and stay asleep.

Granules now has a total of 31 ANDA approvals from US FDA (29 final approvals and two tentative approvals).

Previous:Dr Reddy’s launches dexmedetomidine hydrochloride in 0.9% sodium chloride injection in US

Next:US FDA approves Zydus Cadila’s dimethyl fumarate DR capsules

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service